Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10.
Immunotherapy. 2021.
PMID: 33172323
Clinical Trial.
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD, Alberts SR, Peña C, Genvresse I, Ajavon-Hartmann A, Xia C, Kelly A, Grilley-Olson JE.
Kim RD, et al. Among authors: ajavon hartmann a.
Br J Cancer. 2018 Feb 20;118(4):462-470. doi: 10.1038/bjc.2017.428. Epub 2018 Jan 18.
Br J Cancer. 2018.
PMID: 29348486
Free PMC article.
Clinical Trial.
Item in Clipboard
Response to "Critical Analysis of Apixaban Dose Adjustment Criteria".
Mandt SR, Gaitonde P, Ajavon-Hartmann A, Klem C, Chan A, Bastien A.
Mandt SR, et al. Among authors: ajavon hartmann a.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221078841. doi: 10.1177/10760296221078841.
Clin Appl Thromb Hemost. 2022.
PMID: 35603638
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite